Guidance impact on primary care prescribing rates of simple analgesia: an interrupted time series analysis in England

INTRODUCTION

In light of the current funding deficit in the NHS, it is imperative that spending is made more efficient — a sentiment acknowledged by The NHS Long Term Plan published in 2019. One previously identified key area for improvement is medication optimisation: ensuring medicines are both clinically effective and cost-effective. Pharmaceutical spending is a common source of financial strain on healthcare systems worldwide, and is one of the highest NHS expenditures, second only to staffing. NHS England published guidance in March 2018 specifying medications that should not be routinely prescribed in primary care, including items that are available for purchase over the counter. While this guidance allows for a nationally coordinated response, the decision to implement it as a policy, as well as the choice of implementation strategies, lies with clinical commissioning groups (CCGs) — statutory regional NHS bodies that are responsible for the planning and commissioning of healthcare services for their local area.

Before publication of the prescribing guidance, stakeholder consultation revealed a fear that implementation could perpetuate health inequalities given the consequent need for people to purchase some medications themselves over the counter (OTC), which some individuals may not be able to do. Subgroups thought to be at particular risk were people with disability, older people, those of lower socioeconomic status, or those with a limited capacity for self-care.

The estimated annual spend across the NHS on simple analgesia for minor conditions associated with pain, discomfort, or fever is 38 million GBP; or around 7% of total spending on OTC medication in the year before 2017. The recent NHS England guidance suggests that people should be encouraged to supply their own OTC analgesics for minor conditions such as colds, earache, teething pain, and self-limiting musculoskeletal pain; including those who would normally be exempt from paying the usual prescription charge in England, such as those aged <16 years or >60 years, pregnant females, individuals on income support, and those with one of a specified list of medical conditions. Patients in England pay a fixed per-item prescription charge, which does not necessarily cover the total cost incurred by the NHS in prescribing these medications. However, for those exempt from paying prescription charges, a requirement to purchase their own OTC medications will result in a personal cost.

The aim of this study was to evaluate the impact of the March 2018 NHS England guidance on primary care prescribing of simple analgesia available OTC: paracetamol tablets and suspensions; ibuprofen tablets.
and suspensions; and topical non-steroidal
anti-inflammatory drugs (NSAIDs), as
identified in the guidance. Specifically, the
authors aimed to: explore whether there
has been a change in the prescribing rates
of simple analgesia since the publication of
the guidance; explore the extent to which
individual CCGs have considered and
implemented this guidance; and assess
whether there is any evidence the guidance
has resulted in a health inequality by
socioeconomic deprivation.

METHOD
Description of the guidance
NHS England published the document,
Conditions for Which Over the Counter
Items Should not Routinely be Prescribed In
Primary Care: Guidance for CCGs, in March
2018.5 Aimed at CCGs, this guidance includes
items that can be purchased OTC, often at a
lower personal cost than that which would be
incurred by the NHS (in part due to additional
administrative and dispensing costs), as well
as medications that lack robust evidence for
clinical effectiveness. Some drug classes
are subject to specific exceptions where they
may justifiably be prescribed, for example, it
is suggested that vitamins are not prescribed
except where there is a medically diagnosed
deficiency, osteoporosis, or malnutrition. The
guidance also provides a list of ‘general
exceptions’ — criteria where the guidance
need not apply and OTC medication may be
prescribed by the primary care physician.
These exceptions include where patients
are prescribed a medication for long-term
conditions [such as chronic arthritis], where
patients have complex medical issues
[such as immunosuppression], or where
a medication is being prescribed for an
unlicensed indication.

Data sources
Primary care prescribing data in England
are published by NHS Digital (https://digital.
nhs.uk) on a monthly basis, detailing the
number of items, quantity, and cost of NHS
prescriptions dispensed in the community
by individual primary care practices.6
Monthly datasets were downloaded
from January 2015 to March 2019, up to
12 months after the publication of the NHS
England guidance, hereby also referred to
as the ‘intervention’.

A list of British National Formulary (BNF)
codes was curated for each of the simple
analgesics mentioned in the NHS England
policy (Supplementary Box S1).9 Specifically,
this included paracetamol tablets (up to
500 mg), paracetamol suspensions,
ibuprofen tablets (up to 400 mg), ibuprofen
suspensions, and topical NSAIDs, and
excluded opioid medications. Branded
and generic medications were included.
Prescription-only medications, and those
combined with other drugs [such as
co-codamol], were excluded. The monthly
prescribing datasets were filtered, by BNF
code, to include only simple analgesia.
The number of items of simple analgesia
prescribed by each practice every month
was aggregated. Information on age, sex-
stratified practice list sizes, published
quarterly by NHS Digital,10 was retrieved to
calculate the monthly prescribing rate per
1000 patients. Practice-level socioeconomic
derprivation data, as quantified by the Index
of Multiple Deprivation (IMD) score,11 were
retrieved from Public Health England,12
recoded as quintiles, and linked to
prescribing data as previously described.13

Interrupted time series analysis
Interrupted time series analyses (ITSA)
were conducted using segmented
Poisson regression to elicit an effect of the
intervention on primary care prescribing,
with the number of items prescribed per
month as the dependent variable, using the
total GP-registered population as an offset
variable to model rates.14 The ITSA model
includes month as a linear variable to model
for an underlying linear time trend (with
month in the dataset labelled from 1 to 51, for
the 51 monthly prescribing datasets used),

How this fits in
As part of a medication optimisation
strategy, in March 2018 NHS England
published guidance for clinical
commissioning groups (CCGs) that
included a list of over-the-counter
medications that should not be routinely
prescribed by GPs in the NHS. Specifically
examining simple analgesia, such as
paracetamol and ibuprofen, the authors
found only a small reduction in national
prescribing rates following guidance
publication. Information collected through
freedom of information requests to CCGs
found a diverse approach to guidance
implementation, with some areas having
no plans for implementation. The findings
suggest that guidance publication alone
had little benefit in reducing prescribing
rates. Careful implementation would be
required to achieve the full potential cost-
saving benefit of the guidance to the NHS,
though care needs to be taken to ensure
that implementation does not result in
health inequality, with the patients having
to purchase medication items themselves.
and the intervention as a dummy variable, coded ‘0’ for the pre-intervention period and ‘1’ for the post-intervention period. A second (adjusted) model additionally accounted for seasonality in the underlying prescribing rates, using a harmonic term based on the month of the year and using two sine/cosine pairs per 12-month period.\textsuperscript{13,15} Initial analyses suggested overdispersion of data, so a quasi-Poisson model was used. It was hypothesised that the intervention would result in a level (step) change in the outcome, given how widely the NHS England guidance was reported at the time of publication.\textsuperscript{14,17} Any changes in linear trend after this point would likely be affected by how well the guidance was subsequently implemented, so the authors did not include an analysis of this in the present model. The pre-intervention time period was from January 2015 to March 2018, and the post-intervention time period was from April 2018 to March 2019 for this analysis. There were no documented missing data in the NHS Digital prescribing or practice list size data, and no sensitivity analyses were conducted.

**Association with deprivation**

The association between practice-level IMD score and annual simple analgesia prescribing rates, 12 months before and after the intervention, was tested using univariate and multivariable Poisson regression, the latter adjusted for the practice proportion of males, proportion of those aged >65 years, and practice list size, as the authors have previously found practice age and sex distribution, and practice list size to be confounders for practice-level prescribing of other medications.\textsuperscript{13} Poisson regression analyses are presented as unadjusted (IRRs) or adjusted incidence rate ratios (aIRRs), comparing the relative rate of prescribing in each IMD score quintile with practices in quintile 1 as the reference group (the least deprived quintile). CCG-level prescribing was stratified by deciles and plotted on a choropleth map, with the use of CCG boundary shapefiles published by the Office for National Statistics\textsuperscript{18} to visualise geographic disparity in prescribing rates. The pre-intervention time period was from April 2017 to March 2018 and the post-intervention time period was from April 2018 to March 2019 for this analysis.

A \( P \)-value <0.05 was considered statistically significant. All data were analysed, and all plots generated, using R (version 3.5.3). The template R script is available at https://github.com/sirsazofduck/2020ReichelH.

**Freedom of information requests**

A freedom of information (FOI) request was submitted to all 191 CCGs (as of April 2019) for information concerning their level of consideration and implementation of the NHS England policy, and the prescribing of analgesics available OTC (see Supplementary Box S2 for the full list of questions). As there was considerable diversity in the methods and strength of implementation (from ‘position statements’ to local guideline development, with or without additional education or incentives) as well as in the timing of implementation, which in some cases occurred before the publication of the national guidance, the authors were not able to examine whether or not the strength of implementation was associated with the level magnitude or trend of change of prescribing rates. A qualitative analysis of the CCG responses is outside the scope of the current study and will be conducted separately.

**RESULTS**

**Trends in prescribing rates**

Data from 7914 practices were included across the study period, covering approximately 120 million prescriptions for oral paracetamol, oral ibuprofen, and topical NSAIDs. When considering all medication groups together, there was a statistically significant reduction in the number of items prescribed per 1000 registered patients per month by GPs in England since the introduction of the NHS England guidance in March 2018 (the intervention; crude prescribing rates 42.3 [before intervention] versus 35.5 [after intervention] per 1000 patients per month). After adjusting for an underlying linear decline in prescribing rates over time and seasonality, the intervention was associated with a statistically significant 4.4% level change reduction in prescribing rates (aIRR 0.96, 95% CI = 0.92 to 0.99, \( P = 0.027\), Figure 1). The time- and season-adjusted prescribing rates reduced from 38.5 to 36.6 prescriptions per 1000 per month, from the month before to the month after the intervention.

The ITSAs for each of the subgroups of simple analgesia showed similar trajectories, with all except ibuprofen tablets/capsule, demonstrating a small statistically significant reduction in prescribing rates following the intervention, after accounting for the underlying long-term linear time trend and seasonality (Table 1). The greatest statistically significant level change was seen in ibuprofen suspension (13.2% reduction in prescribing rate, aIRR 0.868, 95% CI = 0.758 to 0.993, \( P = 0.045\), and no
A statistically significant level change was seen in ibuprofen tablets and capsules (aIRR 0.991, 95% CI = 0.931 to 1.055), Table 1. The time series analysis for all individual medication groups can be found in Supplementary Figure S1.

The rate of prescriptions for all but topical NSAIDs had begun to decrease before both the date the guidance was published and the related consultation period for all medication groups analysed (Supplementary Figure S1). Indeed, the rate of topical NSAID prescriptions was steadily increasing. Following the intervention, the immediate level change reduction was not sustained, and prescribing has continued to rise again (Figure 2). The average actual spend on simple analgesia per 1000 patients for the 12-month period after the intervention was 98 GBP, compared with 123 GBP in the 12 months before the intervention. It is not possible to separate how much of this is attributable to the intervention rather than to the underlying time trend. However, using the previous 12 months as a baseline, the statistically significant 4.4% reduction in prescribing associated with the intervention equates to an approximate additional reduction of 5.40 GBP per 1000 patients, or approximately a 320 000 GBP saving to the NHS across England for the year.

**Association between prescribing and deprivation**

In the 12 months before the intervention, there was a higher rate of prescribing of simple analgesia in more deprived practices (329 items per 1000 registered patients in the least deprived decile versus 612 in the most deprived decile; 709 or 710 practices per decile). In the 12 months after the intervention, this association persisted (Figure 3a and 3b), though there was a general reduction in prescribing rates across all deciles (Supplementary Table S1a).

### Table 1. Effect of intervention on prescribing rates of simple analgesia

<table>
<thead>
<tr>
<th>Medication group</th>
<th>Reduction, %</th>
<th>aIRR</th>
<th>95% CI</th>
<th>P-value</th>
<th>Pre-intervention slope (by month)</th>
<th>Post-intervention slope (by month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All simple analgesia</td>
<td>4.4</td>
<td>0.956</td>
<td>0.919 to 0.995</td>
<td>0.027b</td>
<td>-0.22</td>
<td>-0.18</td>
</tr>
<tr>
<td>Paracetamol tablet/capsule</td>
<td>3.9</td>
<td>0.961</td>
<td>0.925 to 0.999</td>
<td>0.05b</td>
<td>-0.15</td>
<td>-0.12</td>
</tr>
<tr>
<td>Paracetamol suspension</td>
<td>9.3</td>
<td>0.907</td>
<td>0.827 to 0.995</td>
<td>0.045b</td>
<td>-0.02</td>
<td>-0.02</td>
</tr>
<tr>
<td>Ibuprofen tablet/capsule</td>
<td>0.9</td>
<td>0.991</td>
<td>0.931 to 1.055</td>
<td>0.772</td>
<td>-0.06</td>
<td>-0.04</td>
</tr>
<tr>
<td>Ibuprofen suspension</td>
<td>13.2</td>
<td>0.868</td>
<td>0.758 to 0.993</td>
<td>0.045b</td>
<td>-0.01</td>
<td>-0.01</td>
</tr>
<tr>
<td>Topical NSAID</td>
<td>9.0</td>
<td>0.910</td>
<td>0.873 to 0.948</td>
<td>&lt;0.001b</td>
<td>0.03</td>
<td>0.03</td>
</tr>
</tbody>
</table>

*aFor all, and for each subgroup of, simple analgesia the percentage reduction in prescribing rates associated with the intervention is given for the time and seasonally adjusted model, along with the aIRR and 95% CIs. The slope coefficients for the linear trends before and after the intervention are shown (as change in prescribing rate per 1000 registered patients per month). bP<0.05. aIRR = adjusted incidence rate ratio. CI = confidence interval. NSAID = non-steroidal anti-inflammatory drug.
In a multivariable Poisson regression analysis, in the 12 months before the intervention, the rate of prescribing of simple analgesia was around 2.5 times higher in practices in the most deprived quintile compared with those in the least deprived quintile (aIRR 2.44, 95% CI = 2.33 to 2.57). Similar differences were found in the 12 months after the intervention (aIRR 2.42, 95% CI = 2.30 to 2.56, for the most versus least deprived quintile, Supplementary Table S1b). The geographical variation of prescribing rates by CCG is shown in a choropleth map (Supplementary Figure S2).

**Guidance implementation by clinical commissioning groups**

FOI requests were submitted to all 191 CCGs (Supplementary Box S2). Of these, 170 (89%) had a formulary for use by primary care prescribers. A total of 172 (90%) CCGs claimed to have given consideration to the NHS England guidance, with 86 (45%) confirming that they had developed their own policy regarding simple analgesia prescribing (28 had a policy before March 2018). A further 68 (36%) released a ‘position statement’ or directly replicated the NHS England guidance, with 18 (9%) others suggesting that a CCG-specific policy was currently under development (data not shown).

Relevant education for prescribers had been provided by 120 (62%) CCGs. A wide variety of strategies had been used, the most common being electronic or written communications; meetings to discuss the policy; and training sessions (including e-learning). Financial incentivisation is being used by 55 (28%) CCGs, with 26 (14%) indicating plans to enforce the guidance (data not shown).

**DISCUSSION**

**Summary**

NHS England published guidance for CCGs in March 2018 to encourage primary care prescribers to rationalise the prescription of medications that were also available for purchase over the counter. Focusing on the impact on simple analgesia prescribing, the authors found that the intervention resulted in a small but statistically significant additional reduction in prescribing rates after accounting for the underlying long-term decline in prescribing and seasonal variation. However, the magnitude of reduction varied with different analgesics, the highest being for ibuprofen suspension. The reasons for this are unclear. Perhaps individuals with short-term self-care conditions that the NHS England guidance targets are more likely to be prescribed suspension ibuprofen, for example, children with acute febrile illness. Formulations that are more likely to be used for longer-term pain management, for example, tablets or capsules may continue to be prescribed in line with the guidance and thus prescribing rates would reduce by a lesser degree than other formulations, such as suspensions, which are less likely to be prescribed for long-term pain management. This could also partly explain the different (increasing) prescribing profiles seen for topical NSAIDs; a prescription for this formulation may be more likely sought for longer-term pain management. There is also the possibility that willingness of patients to purchase simple analgesia over the counter is inversely proportional to the personal cost incurred.
Topical NSAIDs are usually more expensive over the counter than tablet or capsule formulations, therefore prescribers may be more willing to provide a script, especially if a patient qualifies for free prescriptions. However, the underlying reasons for this unusual trend require further exploration.

On exploring whether there was any change in the socioeconomic gradient of prescribing before and after publication of the guidance, the authors found no evidence to suggest a widening of the existing inequality of prescribing rates by Index of Multiple Deprivation score decile. Finally, through FOI requests, the authors found CCGs were employing a range of approaches for implementing the guidance, from no implementation to policy development and education.

The authors were unable to examine the effect of implementation measures given the disparity in how and when CCGs implemented this guidance. However, it is unlikely that CCG implementation resulted in the rapid level change in prescribing found in this study. The wide publicity surrounding the guidance publication may have resulted in immediate modification of prescribing behaviours. Indeed, publicity of guidance and publications has been previously noted to be associated with changes in prescribing, though it is difficult to attribute causation.19,20

Strengths and limitations
The strengths of this study include the inclusion of primary care prescribing across England, with a long lead-in duration before the studied intervention. The analysis of individual CCG implementation measures
provides evidence of heterogeneity in actions across the country, and this is an area where further work is required.

There are limitations in the presented study. Aggregated practice-level prescribing data were used so it was not possible to determine the indications for prescriptions. The deprivation analyses were not adjusted for confounders other than age, sex, and practice list size. Individual patient data would be required to identify and account for other factors that may drive prescribing, such as the presence of chronic disease, the incidence of acute febrile illness, and the overall age distribution of the registered patients. Furthermore, the deprivation analyses required the assumption that each practice only had a single deprivation score. Individual-level data analyses are required to confirm whether or not patients from more deprived backgrounds are not disadvantaged by the guidance. A second limitation surrounds the use of ITSA in general: that the level changes in prescribing rates seen may not have been secondary to the publication of the NHS England guidance but rather to other factors. However, most of the level changes seen were statistically significant and the new guidance was widely publicised, so it is possible this influenced prescribing behaviours. Third, this analysis could not ascertain whether the form of CCG implementation influenced prescribing rates.

Comparison with existing literature

The pre-intervention trend of declining prescribing rates of simple analgesia suggests prior influencing factors. NHS ‘111’ services may have had some impact. In England, the ‘111’ telephone service provides medical advice and signposting to appropriate services. By suggesting treatment plans or pharmacy services, the ‘111’ service may reduce need for patients to seek prescriptions from their GP, and data from the service suggest the frequency of calls taken has increased by about 25% between 2015 and 2019.21 No change in the relationship between practice-level socioeconomic deprivation and prescribing rates of simple analgesia before and after the intervention was found, despite prior concerns around health inequalities. This may in part be due to the general exceptions clause in the guidance, with the higher prescribing rate seen in more deprived practices reflecting a higher prevalence of chronic conditions that require simple analgesia.22 In practice, the requirement for patients to buy simple analgesia themselves risks the least well off, or vulnerable, in society being unable to purchase or access required medication. The authors cannot exclude the creation of such inequality by this guidance based on the results of the present analysis. Furthermore, health inequalities can occur in domains other than deprivation level, such as ethnicity, and these were not considered in the present analysis of aggregate practice-level data. There is also a risk that shifting purchasing responsibility to patients results in additional inappropriate use of OTC simple analgesics. Indeed, inappropriate use has been described to be a risk of purchasing NSAIDs over the counter, with gaps identified in consumer knowledge,21,24 and it is possible that such outcomes are associated with deprivation.

In addition to the finding that many CCGs were replicating the NHS England guidance as policy, or developing their own, some had used or considered additional strategies for implementation, including education, financial incentives, and enforcement. A systematic review found that educational interventions improved prescribing competency in both medical and non-medical prescribers.25 Despite some evidence for their effect,26–28 some have questioned whether the introduction of incentivisation or enforcement may impact the delivery of proper and ethical care.29,30 This notion is particularly concerning here as there are genuine exceptions whereby the prescribing of OTC medications is justified. In addition, it may also leave GPs in breach of their General Medical Services contracts to refuse to prescribe medications outside of the guidance.31 As the present analysis did not compare linear prescribing trend changes before and after guidance publication, the authors are unable to make inferences around the effectiveness of different forms of implementation.

Implications for research and practice

Further work is required to identify which CCG implementation measures bring about the greatest impact on prescribing behaviour. Ultimately, although the promotion of self-care and the use of alternative healthcare avenues may play a key role in medicines optimisation, mere publication of guidance on prescribing restrictions may only result in a modest cost saving to the NHS. CCGs play a key role in ensuring effective implementation, and the value and potential harms of such implementation, including any detrimental effects on the doctor–patient relationship, will need to be the focus of future work.

Funding

Sarah Hillman and Saran Shantikumar are funded by National Institute for Health Research (NIHR) Clinical Lectureships. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the UK’s Department of Health and Social Care. No specific funding was sought for the presented analysis.

Ethical approval

Ethical approval was not required as all data used are publicly available, and there is no published protocol for this study.

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

Open access

This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licenses/by/4.0/).

Discuss this article

Contribute and read comments about this article: bjgp.org/letters
REFERENCES


